![Jean-Pierre Kinet](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jean-Pierre Kinet
Directeur Général chez
iXLife Capital SAS
Profil
Jean-Pierre Kinet was the founder of AB Science SA, serving as Director since 2001.
Dr. Kinet is the founder of ATANIS Biotech AG, serving as Chief Executive Officer since 2021.
Dr. Kinet is also the founder of Astarix.
Dr. Kinet is currently the Chairman & Chief Executive Officer of VAXON Biotech SA since 2010, Chairman of Pharmafast Bio, Director of Qualyst, Inc., Director of Pharmaleads SA since 2010, Trustee at Harvard University, Member-Supervisory Board of EXAIL SAS, Member of National Institutes of Health, Managing Partner of iXLife Capital SAS since 2015, Member-Supervisory Board of iXCore SASU, Professor at Harvard Medical School since 1995, Member-International Strategic Committee of BioWin ASBL, Member of Académie Royale De Médecine De Belgique, Member-Supervisory Board of iXfund SAS, Manager of JPK Consulting LLC, and Manager of Kinet Life Pharma Management.
Former positions include Chairman of Theravectys SAS, Independent Non-Executive Director at UCB SA from 2012 to 2014, Independent Director at Valerio Therapeutics SA from 2016 to 2020, Independent Director at UCB Pharma SA (France), Director-Immunology & Allergy Laboratory at Beth Israel Deaconess Medical Center, Inc. from 2011 to 2014, Independent Director at Genewave SAS, and Principal at National Institute of Allergy & Infectious Diseases.
Education includes a doctorate from the University of Liege.
Postes actifs de Jean-Pierre Kinet
| Sociétés | Poste | Début |
|---|---|---|
Qualyst, Inc.
 Qualyst, Inc. Medical/Nursing ServicesHealth Services Develops technology for drug discovery | Directeur/Membre du Conseil | - |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment Engages in the improvement of health and saving lives | Corporate Officer/Principal | 15/09/2010 |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 16/09/2010 |
BioWin ASBL
 BioWin ASBL Miscellaneous Commercial ServicesCommercial Services Provides support for research and development of biomarkers | Corporate Officer/Principal | 16/08/2011 |
VAXON Biotech SA
 VAXON Biotech SA BiotechnologyHealth Technology Develops therapeutic vaccines for the treatment of cancers | Directeur Général | 25/01/2024 |
Académie Royale De Médecine De Belgique | Corporate Officer/Principal | - |
iXLife Capital SAS
 iXLife Capital SAS Investment ManagersFinance CC is a private equity investment firm specialized in technology venture capital investing and following a hands-on investment approach. The firm invests in early-stage companies developing innovative technologies in high-growth segments of the information and communication technology sector. The firm may also invest in later-stage companies with significant prospects relative to their valuation. They invest primarily in France and Europe, and opportunistically in Israel and North America. They leverage their business network in the US, Israel and Asia to accelerate the international development of their portfolio companies. CC invests an average of 2 million Euros per company over several financing rounds. They favor projects with high technological content and differentiated intellectual property. The firm targets companies active in industries including 1) components and sub-assemblies (display, radio, modulator, switch matrix, sensors, multimedia chips), 2) telecommunication, networking and data center solutions (routers and switches, storage area network equipment, bandwidth managers, performance enhancement platforms, telecommunication access solutions), and 3) infrastructure and enabling software (application servers, e-commerce integration, data management, smart card, cryptology, applications development tools). | Directeur Général | 10/10/2015 |
Pharmaleads SA
 Pharmaleads SA Pharmaceuticals: MajorHealth Technology Designs and develops substrates for enzymes | Directeur/Membre du Conseil | 01/01/2010 |
EXAIL SAS
 EXAIL SAS Aerospace & DefenseElectronic Technology Provides navigation, photonics and maritime autonomy solutions | Directeur/Membre du Conseil | - |
| ░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Anciens postes connus de Jean-Pierre Kinet
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ | ░░░░░░░░░ | - |
| ░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░░ ░░ ░░░░░░░ ░░░░░ ░░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░ ░░░░░░ ░░ ░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Jean-Pierre Kinet
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
79
Relations au 1er degré
26
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 26 |
|---|---|
Qualyst, Inc.
Qualyst, Inc. Medical/Nursing ServicesHealth Services Develops technology for drug discovery | Health Services |
Pharmaleads SA
Pharmaleads SA Pharmaceuticals: MajorHealth Technology Designs and develops substrates for enzymes | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UCB SA
 UCB SA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
EXAIL SAS
EXAIL SAS Aerospace & DefenseElectronic Technology Provides navigation, photonics and maritime autonomy solutions | Electronic Technology |
Valerio Therapeutics SA
 Valerio Therapeutics SA Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of cancer | Health Technology |
UCB Pharma SA (France)
 UCB Pharma SA (France) Pharmaceuticals: MajorHealth Technology Specializes in allergic and respiratory diseases and disorders | Health Technology |
National Institutes of Health
National Institutes of Health General GovernmentGovernment Engages in the improvement of health and saving lives | Government |
Beth Israel Deaconess Medical Center, Inc.
 Beth Israel Deaconess Medical Center, Inc. Hospital/Nursing ManagementHealth Services Provides healthcare services | Health Services |
VAXON Biotech SA
VAXON Biotech SA BiotechnologyHealth Technology Develops therapeutic vaccines for the treatment of cancers | Health Technology |
iXLife Capital SAS
iXLife Capital SAS Investment ManagersFinance CC is a private equity investment firm specialized in technology venture capital investing and following a hands-on investment approach. The firm invests in early-stage companies developing innovative technologies in high-growth segments of the information and communication technology sector. The firm may also invest in later-stage companies with significant prospects relative to their valuation. They invest primarily in France and Europe, and opportunistically in Israel and North America. They leverage their business network in the US, Israel and Asia to accelerate the international development of their portfolio companies. CC invests an average of 2 million Euros per company over several financing rounds. They favor projects with high technological content and differentiated intellectual property. The firm targets companies active in industries including 1) components and sub-assemblies (display, radio, modulator, switch matrix, sensors, multimedia chips), 2) telecommunication, networking and data center solutions (routers and switches, storage area network equipment, bandwidth managers, performance enhancement platforms, telecommunication access solutions), and 3) infrastructure and enabling software (application servers, e-commerce integration, data management, smart card, cryptology, applications development tools). | Finance |
University of Liege
 University of Liege Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
iXCore SASU
 iXCore SASU Investment ManagersFinance Acts as an alternative investment manager | Finance |
National Institute of Allergy & Infectious Diseases
 National Institute of Allergy & Infectious Diseases General GovernmentGovernment Operates as an agency of the United States department of health and human services | Government |
AB Science SA
 AB Science SA Pharmaceuticals: OtherHealth Technology Provides biochemical research services | Health Technology |
Genewave SAS
 Genewave SAS Medical SpecialtiesHealth Technology Develops, manufactures, and markets molecular diagnostic kits and microarray-based instrumentation products | Health Technology |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioWin ASBL
BioWin ASBL Miscellaneous Commercial ServicesCommercial Services Provides support for research and development of biomarkers | Commercial Services |
Theravectys SAS
 Theravectys SAS BiotechnologyHealth Technology Provides biotechnology research services | Health Technology |
Académie Royale De Médecine De Belgique | |
Astarix | |
iXfund SAS | |
JPK Consulting LLC
 JPK Consulting LLC Miscellaneous Commercial ServicesCommercial Services Operates as a consulting firm that specializes in traffic management, public safety planning, and emergency response training activities | Commercial Services |
Kinet Life Pharma Management | |
Pharmafast Bio | |
ATANIS Biotech AG
 ATANIS Biotech AG Miscellaneous Commercial ServicesCommercial Services Engages in clinical allergy research and diagnostic assay development | Commercial Services |
